Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa

医学 氨基糖苷 多粘菌素 铜绿假单胞菌 他唑巴坦 多粘菌素B 抗生素 微生物学 药品 抗药性 重症监护医学 药理学 细菌 抗生素耐药性 生物 亚胺培南 遗传学
作者
Jason M. Pogue,Keith S. Kaye,Michael P. Veve,Twisha S Patel,Anthony Thomas Gerlach,Susan L. Davis,Laura Puzniak,T. M. File,Shannon Olson,Sorabh Dhar,Robert A. Bonomo,Federico Pérez
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:71 (2): 304-310 被引量:215
标识
DOI:10.1093/cid/ciz816
摘要

BACKGROUND: Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor combination that often retains activity against resistant Pseudomonas aeruginosa. The comparative safety and efficacy vs polymyxins or aminoglycosides in this setting remains unknown. METHODS: A retrospective, multicenter, observational cohort study was performed. Patients who received ceftolozane/tazobactam were compared with those treated with either polymyxin or aminoglycoside-based regimens for infections due to drug-resistant P. aeruginosa. Multivariate logistic regression was performed controlling for factors associated with treatment to assess the independent impact of ceftolozane/tazobactam on clinical cure, acute kidney injury (AKI), and in-hospital mortality. RESULTS: A total of 200 patients were included (100 in each treatment arm). The cohort represented an ill population with 69% in the intensive care unit, 63% mechanically ventilated, and 42% in severe sepsis or septic shock at infection onset. The most common infection type was ventilator-associated pneumonia (52%); 7% of patients were bacteremic. Combination therapy was more commonly used in polymyxin/aminoglycoside patients than those who received ceftolozane/tazobactam (72% vs 15%, P < .001). After adjusting for differences between groups, receipt of ceftolozane/tazobactam was independently associated with clinical cure (adjusted odds ratio [aOR], 2.63; 95% confidence interval [CI], 1.31-5.30) and protective against AKI (aOR, 0.08; 95% CI, 0.03-0.22). There was no difference in in-hospital mortality. The number needed to treat for a clinical cure with ceftolozane/tazobactam was 5, and the number needed to harm with AKI with a polymyxin/aminoglycoside was 4. CONCLUSIONS: These data support the preferential use of ceftolozane/tazobactam over polymyxins or aminoglycosides for drug-resistant P. aeruginosa infections.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Orange的应助被LL采纳,获得10
刚刚
刚刚
莫三颜完成签到,获得积分10
刚刚
糖糖糖86发布了新的文献求助30
1秒前
54HUNnnni发布了新的文献求助10
1秒前
dudu发布了新的文献求助10
1秒前
1秒前
2秒前
TT发布了新的文献求助10
3秒前
3秒前
科研通AI6.2的应助被猫南北采纳,获得10
3秒前
3秒前
等DENG发布了新的文献求助10
4秒前
sufu_jony的应助被659采纳,获得10
4秒前
香蕉觅云的应助被喵喵喵采纳,获得10
4秒前
阿申爱乐的应助被zoe采纳,获得30
5秒前
5秒前
ding的应助被孙俏俏采纳,获得10
6秒前
兜哥完成签到,获得积分10
7秒前
chemistry606完成签到 ,获得积分10
7秒前
7秒前
qr完成签到,获得积分10
7秒前
英姑的应助被道中道采纳,获得10
8秒前
8秒前
8秒前
8秒前
9秒前
9秒前
清运盘锦完成签到,获得积分10
9秒前
weiliu完成签到,获得积分10
9秒前
谨慎的静竹完成签到,获得积分10
10秒前
10秒前
Code_king发布了新的文献求助10
11秒前
爱笑的小松鼠完成签到,获得积分10
11秒前
cjzshaoji完成签到,获得积分10
12秒前
Code_king发布了新的文献求助10
12秒前
Code_king发布了新的文献求助10
12秒前
12秒前
无极微光的应助被Amanda采纳,获得20
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176573
求助须知:如何正确求助?哪些是违规求助? 9567927
关于积分的说明 21795369
捐赠科研通 7771232
什么是DOI,文献DOI怎么找? 3432070
关于科研通互助平台的介绍 2556429
邀请新用户注册赠送积分活动 2477707